SE514982C2 - Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning - Google Patents
Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användningInfo
- Publication number
- SE514982C2 SE514982C2 SE9903534A SE9903534A SE514982C2 SE 514982 C2 SE514982 C2 SE 514982C2 SE 9903534 A SE9903534 A SE 9903534A SE 9903534 A SE9903534 A SE 9903534A SE 514982 C2 SE514982 C2 SE 514982C2
- Authority
- SE
- Sweden
- Prior art keywords
- carrier
- hpv
- protein
- human papillomavirus
- polynucleotide
- Prior art date
Links
- 241000701806 Human papillomavirus Species 0.000 title claims abstract description 13
- 101710135729 Major capsid protein L1 Proteins 0.000 title claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 16
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 16
- 239000002157 polynucleotide Substances 0.000 claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 14
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 230000003612 virological effect Effects 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 230000005875 antibody response Effects 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000003071 parasitic effect Effects 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 5
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000000599 auto-anti-genic effect Effects 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 101710163801 Minor capsid protein L2 Proteins 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000002255 vaccination Methods 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 28
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 16
- 239000002245 particle Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108090000565 Capsid Proteins Proteins 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 5
- 241001631646 Papillomaviridae Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000009608 Papillomavirus Infections Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 208000021145 human papilloma virus infection Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000009000 laryngeal papillomatosis Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000001307 recurrent respiratory papillomatosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
Priority Applications (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903534A SE514982C2 (sv) | 1999-09-30 | 1999-09-30 | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
| PL00355012A PL355012A1 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
| RU2002111554/13A RU2002111554A (ru) | 1999-09-30 | 2000-09-19 | Вакцина |
| BR0014666-8A BR0014666A (pt) | 1999-09-30 | 2000-09-19 | Vacina |
| MXPA02003328A MXPA02003328A (es) | 1999-09-30 | 2000-09-19 | Vacuna. |
| PCT/SE2000/001808 WO2001023422A1 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
| AT00966633T ATE313559T1 (de) | 1999-09-30 | 2000-09-19 | Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen |
| CA002384723A CA2384723A1 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
| DE60025016T DE60025016D1 (de) | 1999-09-30 | 2000-09-19 | Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen |
| YU22202A YU22202A (sh) | 1999-09-30 | 2000-09-19 | Vakcina |
| AU76951/00A AU771481B2 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
| CZ20021023A CZ20021023A3 (cs) | 1999-09-30 | 2000-09-19 | Vakcína |
| SK422-2002A SK4222002A3 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
| TR2002/00802T TR200200802T2 (tr) | 1999-09-30 | 2000-09-19 | Aşı |
| IL14874100A IL148741A0 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
| HU0202770A HUP0202770A3 (en) | 1999-09-30 | 2000-09-19 | Human papilloma virus vaccine |
| EEP200200157A EE200200157A (et) | 1999-09-30 | 2000-09-19 | Vaktsiin |
| JP2001526572A JP2003510064A (ja) | 1999-09-30 | 2000-09-19 | ワクチン |
| CN00812618A CN1373771A (zh) | 1999-09-30 | 2000-09-19 | 疫苗 |
| KR1020027004124A KR20020047195A (ko) | 1999-09-30 | 2000-09-19 | 백신 |
| NZ516725A NZ516725A (en) | 1999-09-30 | 2000-09-19 | Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus |
| EP00966633A EP1222200B1 (en) | 1999-09-30 | 2000-09-19 | Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof |
| HR20020092A HRP20020092A2 (en) | 1999-09-30 | 2002-01-29 | Vaccine |
| ZA200200886A ZA200200886B (en) | 1999-09-30 | 2002-01-31 | Vaccine. |
| NO20020615A NO20020615L (no) | 1999-09-30 | 2002-02-08 | Vaksine |
| US10/759,125 US20040146531A1 (en) | 1999-09-30 | 2004-01-20 | Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells |
| AU2004201964A AU2004201964A1 (en) | 1999-01-15 | 2004-05-10 | Bandwidth transfer switching system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903534A SE514982C2 (sv) | 1999-09-30 | 1999-09-30 | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9903534D0 SE9903534D0 (sv) | 1999-09-30 |
| SE9903534L SE9903534L (sv) | 2001-03-31 |
| SE514982C2 true SE514982C2 (sv) | 2001-05-28 |
Family
ID=20417209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9903534A SE514982C2 (sv) | 1999-01-15 | 1999-09-30 | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1222200B1 (pt) |
| JP (1) | JP2003510064A (pt) |
| KR (1) | KR20020047195A (pt) |
| CN (1) | CN1373771A (pt) |
| AT (1) | ATE313559T1 (pt) |
| AU (1) | AU771481B2 (pt) |
| BR (1) | BR0014666A (pt) |
| CA (1) | CA2384723A1 (pt) |
| CZ (1) | CZ20021023A3 (pt) |
| DE (1) | DE60025016D1 (pt) |
| EE (1) | EE200200157A (pt) |
| HR (1) | HRP20020092A2 (pt) |
| HU (1) | HUP0202770A3 (pt) |
| IL (1) | IL148741A0 (pt) |
| MX (1) | MXPA02003328A (pt) |
| NO (1) | NO20020615L (pt) |
| NZ (1) | NZ516725A (pt) |
| PL (1) | PL355012A1 (pt) |
| RU (1) | RU2002111554A (pt) |
| SE (1) | SE514982C2 (pt) |
| SK (1) | SK4222002A3 (pt) |
| TR (1) | TR200200802T2 (pt) |
| WO (1) | WO2001023422A1 (pt) |
| YU (1) | YU22202A (pt) |
| ZA (1) | ZA200200886B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| CA2560487C (en) * | 2004-03-24 | 2013-01-29 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
| DE102004036913A1 (de) * | 2004-07-16 | 2006-02-09 | Responsif Gmbh | Verwendung von Pentameren zur Herstellung eines Medikaments |
| CN1796403B (zh) * | 2004-12-22 | 2010-04-28 | 三峡大学 | 用于多型人乳头瘤病毒感染防治的多肽和疫苗 |
| CN100392084C (zh) * | 2006-03-13 | 2008-06-04 | 曾毅 | 含密码子优化型hpv16l1基因的重组腺病毒 |
| CN101914139B (zh) * | 2010-07-16 | 2012-11-21 | 四川大学 | 人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用 |
| MY202196A (en) | 2017-06-23 | 2024-04-16 | Verimmune Inc | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses |
| CN113396155A (zh) | 2018-12-27 | 2021-09-14 | 维伊木恩股份有限公司 | 偶联病毒样颗粒及其作为抗肿瘤免疫重定向剂的用途 |
| WO2020163853A1 (en) * | 2019-02-08 | 2020-08-13 | Rensselaer Polytechnic Institute | A contraceptive vaccine based on the sperm-associated protein catsper |
| JP2023552040A (ja) | 2020-10-19 | 2023-12-14 | ヴェリミューン インコーポレイテッド | ウイルスにインスパイアされた組成物及びがんの治療のために同じものを使用して、既存の免疫応答をリダイレクトする方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE325875T1 (de) * | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| FR2768749A1 (fr) * | 1997-09-22 | 1999-03-26 | Inst Nat Sante Rech Med | Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique |
| DE19812941A1 (de) * | 1998-03-24 | 1999-10-07 | Medigene Ag | Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor |
-
1999
- 1999-09-30 SE SE9903534A patent/SE514982C2/sv not_active IP Right Cessation
-
2000
- 2000-09-19 PL PL00355012A patent/PL355012A1/xx not_active Application Discontinuation
- 2000-09-19 EP EP00966633A patent/EP1222200B1/en not_active Expired - Lifetime
- 2000-09-19 IL IL14874100A patent/IL148741A0/xx unknown
- 2000-09-19 SK SK422-2002A patent/SK4222002A3/sk unknown
- 2000-09-19 JP JP2001526572A patent/JP2003510064A/ja active Pending
- 2000-09-19 CZ CZ20021023A patent/CZ20021023A3/cs unknown
- 2000-09-19 AT AT00966633T patent/ATE313559T1/de not_active IP Right Cessation
- 2000-09-19 DE DE60025016T patent/DE60025016D1/de not_active Expired - Lifetime
- 2000-09-19 HU HU0202770A patent/HUP0202770A3/hu unknown
- 2000-09-19 MX MXPA02003328A patent/MXPA02003328A/es unknown
- 2000-09-19 NZ NZ516725A patent/NZ516725A/xx unknown
- 2000-09-19 TR TR2002/00802T patent/TR200200802T2/xx unknown
- 2000-09-19 RU RU2002111554/13A patent/RU2002111554A/ru unknown
- 2000-09-19 WO PCT/SE2000/001808 patent/WO2001023422A1/en active IP Right Grant
- 2000-09-19 CA CA002384723A patent/CA2384723A1/en not_active Abandoned
- 2000-09-19 EE EEP200200157A patent/EE200200157A/xx unknown
- 2000-09-19 BR BR0014666-8A patent/BR0014666A/pt not_active IP Right Cessation
- 2000-09-19 CN CN00812618A patent/CN1373771A/zh active Pending
- 2000-09-19 YU YU22202A patent/YU22202A/sh unknown
- 2000-09-19 AU AU76951/00A patent/AU771481B2/en not_active Ceased
- 2000-09-19 KR KR1020027004124A patent/KR20020047195A/ko not_active Application Discontinuation
-
2002
- 2002-01-29 HR HR20020092A patent/HRP20020092A2/hr not_active Application Discontinuation
- 2002-01-31 ZA ZA200200886A patent/ZA200200886B/en unknown
- 2002-02-08 NO NO20020615A patent/NO20020615L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202770A3 (en) | 2004-07-28 |
| SE9903534L (sv) | 2001-03-31 |
| CN1373771A (zh) | 2002-10-09 |
| WO2001023422A1 (en) | 2001-04-05 |
| RU2002111554A (ru) | 2004-03-27 |
| HUP0202770A2 (hu) | 2002-12-28 |
| EP1222200A1 (en) | 2002-07-17 |
| CZ20021023A3 (cs) | 2002-07-17 |
| NZ516725A (en) | 2003-03-28 |
| IL148741A0 (en) | 2002-09-12 |
| NO20020615L (no) | 2002-05-29 |
| MXPA02003328A (es) | 2004-09-10 |
| SE9903534D0 (sv) | 1999-09-30 |
| PL355012A1 (en) | 2004-03-22 |
| AU7695100A (en) | 2001-04-30 |
| JP2003510064A (ja) | 2003-03-18 |
| HRP20020092A2 (en) | 2003-06-30 |
| TR200200802T2 (tr) | 2002-09-23 |
| YU22202A (sh) | 2005-06-10 |
| KR20020047195A (ko) | 2002-06-21 |
| BR0014666A (pt) | 2002-06-18 |
| NO20020615D0 (no) | 2002-02-08 |
| DE60025016D1 (de) | 2006-01-26 |
| CA2384723A1 (en) | 2001-04-05 |
| EP1222200B1 (en) | 2005-12-21 |
| SK4222002A3 (en) | 2002-10-08 |
| ZA200200886B (en) | 2003-03-26 |
| AU771481B2 (en) | 2004-03-25 |
| ATE313559T1 (de) | 2006-01-15 |
| EE200200157A (et) | 2003-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jochmus et al. | Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine | |
| Gambhira et al. | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2 | |
| Christensen et al. | Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus | |
| Christensen et al. | Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies | |
| Kondo et al. | Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region | |
| Jagu et al. | Optimization of multimeric human papillomavirus L2 vaccines | |
| Palmer et al. | Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes | |
| Campo et al. | Papillomavirus prophylactic vaccines: established successes, new approaches | |
| Shi et al. | Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses | |
| Fligge et al. | Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33 | |
| US6887478B2 (en) | Formalin-treated human papillomavirus L1 protein vaccine | |
| Jagu et al. | A multimeric L2 vaccine for prevention of animal papillomavirus infections | |
| EP1222200B1 (en) | Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof | |
| Liu et al. | Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses | |
| AU2003232951B2 (en) | Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles. | |
| EP0957936B1 (en) | Formulations of recombinant papillomavirus vaccines | |
| García-Silva et al. | Virus-like particle-based vaccines against SARS-CoV-2 | |
| US20040146531A1 (en) | Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells | |
| Ellis | The new generation of recombinant viral subunit vaccines | |
| Sapp et al. | Synthesis, properties and applications of papillomavirus-like particles | |
| Deng et al. | The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro | |
| WO2008115631A9 (en) | Plant-produced compositions for treating papillomavirus infection and related methods | |
| WO1996033737A1 (en) | Peptide-based vaccine against papillomavirus infection | |
| US20100221280A1 (en) | Plant-produced compositions for treating papillomavirus infection and related methods | |
| Kazaks et al. | 11 Papillomavirus-Derived Virus-Like Particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |